Back to Journals » Drug Design, Development and Therapy » Volume 9

Sphingosine kinase 1 as an anticancer therapeutic target

Authors Gao Y, Gao F, Chen K, Tian M, Zhao D

Received 21 February 2015

Accepted for publication 29 April 2015

Published 23 June 2015 Volume 2015:9 Pages 3239—3245


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Professor Shu-Feng Zhou

Ying Gao,1,* Fei Gao,2,* Kan Chen,3,* Mei-li Tian,1 Dong-li Zhao1

1Department of Radiotherapy Oncology, First Affiliated Hospital of Xi’an Jiaotong University, 2Department of Neurology, First Affiliated Hospital of Xi’an Medical University, Xi’an, 3School of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People’s Republic of China

*These authors contributed equally to this work

Abstract: The development of chemotherapeutic resistance is a major challenge in oncology. Elevated sphingosine kinase 1 (SK1) levels is predictive of a poor prognosis, and SK1 overexpression may confer resistance to chemotherapeutics. The SK/sphingosine-1-phosphate (S1P)/sphingosine-1-phosphate receptor (S1PR) signaling pathway has been implicated in the progression of various cancers and in chemotherapeutic drug resistance. Therefore, SK1 may represent an important target for cancer therapy. Targeting the SK/S1P/S1PR signaling pathway may be an effective anticancer therapeutic strategy, particularly in the context of overcoming drug resistance. This review summarizes our current understanding of the role of SK/S1P/S1PR signaling in cancer and development of SK1 inhibitors.

Keywords: sphingosine kinase 1, S1P, S1PR, inhibitors, cancer, therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]